ALK | Allergy solutions for life
ALK

Pioneering in the field of respiratory allergies for more than a century, we've embarked on a mission to help more people, with more solutions, more efficiently.

News

  • Post date
    03/07/2025
    ACARIZAX® approved in Canada for treatment of young children
  • Post date
    03/04/2025
    Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
  • Post date
    02/27/2025
    FDA approves ODACTRA® for the treatment of house dust mite allergy in young children
ALK corporate strategy 2024-2028
As the pioneers of allergy solutions, we are stepping into the next 100 years with a mission to help more people, with more solutions, more efficiently. We call it Allergy+.
Image
ALK homepage video thumbnail
We are the pioneers of allergy solutions

For more than a 100 years, ALK has been at the forefront of allergy research and treatment. We're on a mission to help even more people globally, reaching 5 million people a year by 2030.

ALK in brief

Avatar

Allergy solutions

Allergy is caused by an overreaction of the body’s immune system to substances that in most cases would otherwise be harmless. Learn about the chronic disease, diagnosis, and treatment options.

Avatar

Sustainability

We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.

Avatar

Careers

Become part of a team that is passionate about making a difference for people living with allergy. In our global company, we share expertise and knowledge across boarders and cultures and have a focus on continuous employee development.